Yipeng Pan

Dr. Yipeng Pan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XZXu-Guang Zhang
Xu-Guang Zhang
ALAi-Xia Liu
Ai-Xia Liu
YZYu-Xin Zhang
Yu-Xin Zhang
MZMingyan Zhou
Mingyan Zhou
XLXiang-Yi Li
Xiang-Yi Li
JZJunqing Zhang
Junqing Zhang

8 June 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XLXiaoliang Li
Xiaoliang Li
MZMingyan Zhou
Mingyan Zhou
ZZZhe Zhu
Zhe Zhu
ZWZhe Wang
Zhe Wang
XZXuguang Zhang
Xuguang Zhang
JXJian Xu
Jian Xu

30 May 2024 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
XLXiaoliang Li
Xiaoliang Li
MZMingyan Zhou
Mingyan Zhou
WCWeijia Chen
Weijia Chen
JSJiangbo Sun
Jiangbo Sun
YZYihang Zhao
Yihang Zhao
JXJian Xu
Jian Xu
Background: Galangin, a flavonoid compound, is derived from Alpinia officinarum Hance. Previous studies have shown that galangin can inhibit the proliferation of hepatocellular carcinoma (HCC), but its mechanism is still unclear. This study aims to investigate the potential targets and molecular mechanisms of galangin on HCC through network pharmacology, bioinformatics, molecular docking, and experimental in vitro validation. Methods: In this study, network pharmacology was used to investigate the targets and mechanisms of galangin in the treatment of HCC. AutoDockTools software was used to simulate and calculate the binding of galangin to its core targets. GO and KEGG enrichment analyses were conducted in the DAVID database to explore the main biological functions and signaling pathways impacted by galangin intervention. In addition, bioinformatics was applied to examine the correlation between the differential expressions of the anti-HCC core targets of galangin and the survival of patients with HCC. Finally, the findings obtained from network pharmacology and bioinformatics were verified in cell experiments. Results: A total of 67 overlapping target genes of galangin and HCC were identified. Through the analysis of the protein-protein interaction (PPI) network, 10 hub genes with the highest degree of freedom were identified, including SRC, ESR1, MMP9, CDK4, CCNB1, MMP2, CDK2, CDK1, CHK1, and PLK1. These genes were found to be closely related to the degradation of the extracellular matrix, signal transduction, and the cell cycle. GO and KEGG enrichment analyses revealed that galangin exerts an anti-HCC role by affecting various signaling pathways, including the cell cycle, pathways in cancer, and the PI3K-Akt signaling pathway. The results of molecular docking indicated a significant interaction between galangin and CCNB1, CDK4, CDK1, and PLK1. Bioinformatics analysis revealed that CCNB1, CDK4, CDK1, and PLK1 were upregulated in the liver of patients with HCC at both the mRNA and protein levels. Flow cytometry analysis showed that galangin induced G0/G1 phase arrest and cell apoptosis in HepG2 and Huh7 cells. Additionally, galangin suppressed the expression of key proteins and mRNAs involved in the cell cycle pathway. Conclusions: These results suggest that galangin inhibits the growth of HCC cells by arresting the cell cycle at the G0/G1 phase.

6 November 2023 in Fitoterapia
Verified
Journal Article
Closed access
XZXiuwen Zheng
Xiuwen Zheng
YZYuxin Zhang
Yuxin Zhang
YTYinfeng Tan
Yinfeng Tan
YLYonghui Li
Yonghui Li
QXQianrong Xue
Qianrong Xue
JZJunqing Zhang
Junqing Zhang

26 January 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XZXiuwen Zheng
Xiuwen Zheng
QXQianrong Xue
Qianrong Xue
YWYinghuan Wang
Yinghuan Wang
LLLu Lu
Lu Lu
YPYipeng Pan
Yipeng Pan
JZJunqing Zhang
Junqing Zhang

23 April 2024 in Heliyon
Verified
Journal Article
Open access
GMGu-Xu Ming
Gu-Xu Ming
JLJun-Yan Liu
Jun-Yan Liu
YWYu-Huang Wu
Yu-Huang Wu
LLLi-Yan Li
Li-Yan Li
XMXin-Yue Ma
Xin-Yue Ma
YLYonghui Li
Yonghui Li
Nauclea officinalis, as a Chinese medicine in Hainan province, had the effect of treating lower limb ulcers, burn infections. In this paper, we studied the effect of Strictosamide (STR), the main bioactive compound in Nauclea officinals, on wound healing and explored its internal mechanism. Firstly, the wound healing potential of STR was evaluated in a rat model, demonstrating its ability to expedite wound healing, mitigate inflammatory infiltration, and enhance collagen deposition. Additionally, immunofluorescence analysis revealed that STR up-regulated the expression of CD31 and PCNA. Subsequently, target prediction, protein-protein interaction (PPI), gene ontology (GO), and pathway enrichment analyses were used to obtain potential targets, specific biological processes, and molecular mechanisms of STR for the potential treatment of wound healing. Furthermore, molecular docking was conducted to predict the binding affinity between STR and its associated targets. Additionally, in vivo and in vitro experiments confirmed that STR could increase the expression of P-PI3K, P-AKT and P-mTOR by activating the PI3K/AKT signaling pathway. In summary, this study provided a new explanation for the mechanism by which STR promotes wound healing through network pharmacology, suggesting that STR may be a new candidate for treating wound.